Clinical Trial: Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07471841) titled 'Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax' on March 10.

Brief Summary: This is a prospective, single-arm phase 2 pilot study to assess the response rate of IDH1 mutated relapsed/refractory acute myeloid leukemia (AML) patients who receive olutasidenib after progressing on venetoclax based regimens. Each cycle will last for 28 days. Patients will receive olutasidenib 150 mg orally twice daily Day 1 through Day 28. After 3 cycles of olutasidenib, azacitidine 75 mg/m2 given on Day 1 through Day 7 may be added at the discretion of the treating investigator if the patient has not achieved...